Small Molecule Deal Benchmarks in Metabolic & Obesity

Median Upfront

$683M

Range: $375M - $979M

Total Deal Value

$3.2B

Range: $2.1B - $4.4B

Royalty Rate

14.6% - 26.7%

Tiered up to 30.7%

Dev Milestones

$460M

Range: $311M - $610M

Model Your Deal

Market Analysis

Small Molecule therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 small molecule asset in metabolic & obesity is $683M, with total deal values reaching $3.2B. Development milestones average $460M, while regulatory milestones contribute $562M.

The metabolic & obesity small molecule landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for small molecule metabolic & obesity deals range from 14.6% to 26.7% at the base tier, with tiered escalation reaching 18.6%-30.7% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a small molecule metabolic & obesity licensing deal?

Based on our analysis, Phase 2 small molecule licensing deals in metabolic & obesity average $683M in upfront payments, with a range of $375M to $979M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for small molecule metabolic & obesity transactions?

The median total deal value for Phase 2 small molecule assets in metabolic & obesity is $3.2B, ranging from $2.1B to $4.4B. This includes development milestones ($460M), regulatory milestones ($562M), and commercial milestones ($1.5B).

What royalty rates are standard for small molecule deals in metabolic & obesity?

Base royalty rates for small molecule metabolic & obesity transactions range from 14.6% to 26.7%, with tiered escalations reaching 18.6%-30.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in small molecule metabolic & obesity deals?

Small Molecule metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($460M) make up the largest share, followed by commercial milestones ($1.5B) and regulatory milestones ($562M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Small Molecule Deal Benchmarks in Metabolic & Obesity

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

GLP-1 Agonist in Metabolic & Obesity

Dual Incretin in Metabolic & Obesity

Small Molecule in Oncology

Small Molecule in Neurology

Ready to Calculate Your Deal Terms?